# Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT

> **NCT02980653** · PHASE2 · UNKNOWN · sponsor: **TTY Biopharm** · enrollment: 105 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Megestrol acetate (MA) 400 mg/day

## Key facts

- **NCT ID:** NCT02980653
- **Lead sponsor:** TTY Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2017-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980653, "Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02980653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*